Fatty Liver Has Overtaken Hepatitis B as China's Most Common Liver Disease
For decades viral hepatitis was the liver disease Chinese people feared most. Better hygiene and vaccination have pushed it down — and a fattier, more sedentary way of life has pushed metabolic fatty liver to the top, with prevalence estimates of 30 to 40 percent and a firm grip on the young.
For most of modern Chinese medical history, the liver disease to fear was infectious: hepatitis B, which infected perhaps a tenth of the population at its peak and carried a heavy stigma — discriminatory schooling and hiring rules survived into this century. A decade of vaccination drives and better antiviral treatment has brought viral hepatitis under control. What has replaced it at the top of the charts is a disease of prosperity.
Fatty liver — specifically metabolic dysfunction-associated fatty liver disease — is now the most common chronic liver disease in China, with prevalence estimated at 30 to 40 percent, and it is spreading fastest among young people. An explainer published by the science outlet Kepu China, which has been passed around Weibo this week under the heading "Previously it was hepatitis B — now China's biggest liver disease has become this, and it is eroding young people," traces the shift plainly: as incomes rose, so did obesity, now affecting more than half the population by some estimates, and with it the metabolic syndrome that packs fat into the liver.
The phrase doing the work in Chinese coverage is "富贵病" — a disease of the well-fed. It is an old coinage for diabetes and gout, conditions that once marked their bearers as unusually prosperous. Fatty liver's arrival in the same category is the epidemiology of the last forty years compressed into a diagnosis: economic success measured in waistlines. Public-health campaigns that once centred on vaccination and clean needles now compete with delivery apps, long working hours and a food culture that has never been more abundant.
What makes the trend line serious is the treatment picture. There is no approved drug that reliably reverses fatty liver; the prescription is weight loss, exercise and less alcohol, delivered one patient at a time. Left uncontrolled, it can progress to cirrhosis and liver cancer — and because early fatty liver is silent, clinicians keep repeating the same advice: screen early, before symptoms. Health authorities have been running liver-health campaigns each March for years, but the disease's expansion down the age brackets is outpacing them.
China is not alone in this — fatty liver is climbing across every wealthy and middle-income country — but the scale is distinctive: more than 200 million Chinese are estimated to have some form of it. The question the week's coverage leaves open is whether a health system built to defeat infections can retool itself, quickly enough, to defeat abundance.